Regulatory and Safety: Obesity Drugs


Diabetes & Obesity Series

Safety and Regulatory Aspects of Obesity Drugs

Subscribe to RSS feed of this series

Dr. David Orloff
Executive Director of Regulatory Affairs

Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.

Others in the Series

Diabetes Resources

Associations and Societies

Clinical Trials

Obesity Resources

Articles, Multimedia

Associations and Societies

Clinical Trials

Related Content
© 2024 MJH Life Sciences

All rights reserved.